Ponatinib also produces an improvement in progression-free survival compared with imatinib among those with Philadelphia chromosome-positive acute lymphoblastic leukemia in the phase 3 PhALLCON trial.

In an analysis of the phase III CEPHEUS trial presented at the American Society of Hematology annual meeting, adding daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and ...

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and ...

Researchers found that the outcomes were excellent for the 178 end of first consolidation measurable residual disease (MRD)-negative patients, regardless of MRD results at later time points. HealthDay ...

Iclusig plust reduced-intensity bested Gleevec when it came to MRD-negative complete remission in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Adding Iclusig (ponatinib ...

TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...

Please provide your email address to receive an email when new articles are posted on . Those who sustained MRD negativity for more than 6 months achieved longer response duration and PFS. All ...

In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after prior treatment, experienced comparable outcomes whether they received ...